177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
Status:
Recruiting
Trial end date:
2025-07-31
Target enrollment:
Participant gender:
Summary
177Lu PSMA 617 is a new type of therapy which is designed to deliver high doses of radiation
directly to prostate cancer sites in the body. The purpose of this study is to find out
whether 177Lu PSMA 617can slow the growth of prostate cancer compared to standard
chemotherapy treatment